UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
_______________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 1, 2017
BIOMERICA, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 0-8765 | 95-2645573 |
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| | 17571 Von Karman Ave. Irvine, California | 92614 |
| | (Address of Principal Executive Offices) | (Zip Code) |
Registrant's telephone number, including area code: (949) 645-2111
Not Applicable
(Former name or former address if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 8.01 Other:
Approval by Mexico’s COFEPRIS and entry into distribution agreement
The Company announced that it had received approval by Mexico’s COFEPRIS for its colorectal screening test and had appointed DNA Biopharma (DNA) as its exclusive distributor for its EZ Detect product in Mexico. See the attached Press Release in the Exhibit Index.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | |
| | BIOMERICA, INC. | ||
| | | | |
| Date: March 8, 2018 | By: | | /s/ Zackary S. Irani |
| | | | Zackary S. Irani |
EXHIBIT INDEX
Biomerica Press Release Dated March 8, 2018